{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:10:23Z","timestamp":1794643823646,"version":"4.9.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T00:00:00Z","timestamp":1503360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T00:00:00Z","timestamp":1503360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["D43TW009771"],"award-info":[{"award-number":["D43TW009771"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI001040"],"award-info":[{"award-number":["AI001040"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2680-6","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T14:51:06Z","timestamp":1503413466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-6525","authenticated-orcid":false,"given":"Victor","family":"Ssempijja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertrude","family":"Nakigozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Ndyanabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingo","family":"Kasule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Serwadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja van\u2019t","family":"Hoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven James","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"2680_CR1","unstructured":"WHO.HIV\/AIDS: Consolidated guidelines on the use of antiretroviral (ART) drugs for treating and preventing HIV infection. In. June, 2013 ed. \n                    http:\/\/apps.who.int\/iris\/handle\/10665\/85322\n                    \n                  ( Accessed 31 May 2016); 2013."},{"issue":"1","key":"2680_CR2","doi-asserted-by":"publisher","first-page":"ofw018","DOI":"10.1093\/ofid\/ofw018","volume":"3","author":"HO Ramadhani","year":"2016","unstructured":"Ramadhani HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, et al. The effect of switching to second-line antiretroviral therapy on the risk of opportunistic infections among patients infected with human immunodeficiency virus in northern Tanzania. Open Forum Infect Dis. 2016;3(1):ofw018.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2680_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-3156.2009.02445.x","volume":"15","author":"O Keiser","year":"2010","unstructured":"Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, Boulle A, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health. 2010;15(2):251\u20138.","journal-title":"Trop Med Int Health"},{"key":"2680_CR4","doi-asserted-by":"crossref","unstructured":"Fairlie L, Karalius B, Patel K, van Dyke RB, Hazra R, Hernan MA, et al. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. In: AIDS (London, England). 2015\/07\/17 ed; 2015. pp. 2109-19.","DOI":"10.1097\/QAD.0000000000000809"},{"issue":"12","key":"2680_CR5","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1089\/aid.2011.0352","volume":"28","author":"SJ Reynolds","year":"2012","unstructured":"Reynolds SJ, Laeyendecker O, Nakigozi G, Gallant JE, Huang W, Hudelson SE, et al. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. AIDS Res Hum Retrovir. 2012;28(12):1739\u201344.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"4","key":"2680_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/QAD.0b013e3283437c2b","volume":"25","author":"SJ Reynolds","year":"2011","unstructured":"Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS (London, England). 2011;25(4):473\u20137.","journal-title":"AIDS (London, England)"},{"key":"2680_CR7","doi-asserted-by":"crossref","unstructured":"Guichet E, Aghokeng AF, Serrano L, Bado G, Toure-Kane C, Eymard-Duvernay S, et al. High viral load and multidrug resistance due to late switch to second-line regimens could be a major obstacle to reach the 90-90-90 UNAIDS objectives in sub-Saharan Africa. AIDS Res Hum Retrovir. 2016;","DOI":"10.1089\/aid.2016.0010"},{"key":"2680_CR8","unstructured":"WHO.HIV\/AIDS:. Monitoring response to ART and diagnosis of treatment failure. In. June, 2013 ed. \n                    http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/art\/artmonitoring\/en\/\n                    \n                   (Accessed 31 May 2016); 2013."},{"issue":"1","key":"2680_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/09540121.2010.498867","volume":"23","author":"J Landier","year":"2011","unstructured":"Landier J, Akonde A, Pizzocolo C, Haidara I, Drabo M, Pizarro L, et al. Switch to second-line ART in west African routine care: incidence and reasons for switching. AIDS Care. 2011;23(1):75\u20138.","journal-title":"AIDS Care"},{"issue":"12","key":"2680_CR10","doi-asserted-by":"publisher","first-page":"e82724","DOI":"10.1371\/journal.pone.0082724","volume":"8","author":"Y Madec","year":"2013","unstructured":"Madec Y, Leroy S, Rey-Cuille MA, Huber F, Calmy A. Persistent difficulties in switching to second-line ART in sub-saharan Africa--a systematic review and meta-analysis. PLoS One. 2013;8(12):e82724.","journal-title":"PLoS One"},{"issue":"7","key":"2680_CR11","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/S2352-3018(15)00087-9","volume":"2","author":"AD Haas","year":"2015","unstructured":"Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and switching of first-line antiretroviral therapy in sub-Saharan Africa: collaborative analysis of adult treatment cohorts. The lancet HIV. 2015;2(7):e271\u20138.","journal-title":"The lancet HIV"},{"issue":"14","key":"2680_CR12","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1097\/QAD.0000000000000349","volume":"28","author":"ML Petersen","year":"2014","unstructured":"Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, et al. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS (London, England). 2014;28(14):2097\u2013107.","journal-title":"AIDS (London, England)"},{"issue":"5","key":"2680_CR13","doi-asserted-by":"publisher","first-page":"e0127235","DOI":"10.1371\/journal.pone.0127235","volume":"10","author":"A Billioux","year":"2015","unstructured":"Billioux A, Nakigozi G, Newell K, Chang LW, Quinn TC, Gray RH, et al. Durable suppression of HIV-1 after Virologic monitoring-based antiretroviral adherence counseling in Rakai, Uganda. PLoS One. 2015;10(5):e0127235.","journal-title":"PLoS One"},{"issue":"446","key":"2680_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"2680_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1086\/593312","volume":"48","author":"L Palombi","year":"2009","unstructured":"Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, Scarcella P, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis. 2009;48(1):115\u201322.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"2680_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/QAD.0b013e32832e05b2","volume":"23","author":"O Keiser","year":"2009","unstructured":"Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (London, England). 2009;23(14):1867\u201374.","journal-title":"AIDS (London, England)"},{"key":"2680_CR17","unstructured":"WHO. HIV\/AIDS: Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. In. September 2015 ed. 2015. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/186275\/1\/9789241509565_eng.pdf\n                    \n                  . Accessed 10 Apr 2017."},{"key":"2680_CR18","unstructured":"WHO. HIV\/AIDS. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 revision. Geneva; 2010. \n                    http:\/\/www.who.int\/hiv\/pub\/arv\/adult2010\/en\/\n                    \n                  ."},{"issue":"6","key":"2680_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/QAD.0b013e3283262a78","volume":"23","author":"SJ Reynolds","year":"2009","unstructured":"Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (London, England). 2009;23(6):697\u2013700.","journal-title":"AIDS (London, England)"},{"key":"2680_CR20","unstructured":"Centers for Disease Control and Prevention (CDC) A, USA. Scale-up of HIV Viral Load Monitoring \u2014 Seven Sub-Saharan African Countries. In. November 27, 2015 ed. MMWR Morb Mortal Wkly Rep. 2015:1287\u201390. \n                    https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6446a3.htm#Tab1:\n                    \n                  . Accessed 04 July 2016."},{"key":"2680_CR21","unstructured":"UNAIDS.90\u201390-90:. An ambitious treatment target to help end the AIDS epidemic. In. October,2014 ed. \n                    http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/90-90-90_en_0.pdf\n                    \n                   (accessed 5 Apr 2015). 2014."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2680-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-017-2680-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2680-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T11:24:28Z","timestamp":1589455468000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2680-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2680"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2680-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,22]]},"assertion":[{"value":"23 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The retrospective use of de-identified, routinely collected clinical data was approved by the Uganda Virus Research Institute\u2019s Research and Ethics Committee, The Institutional Review Board for Johns Hopkins University School of Medicine, and the Uganda National Council for Science and Technology. Individual informed consent was not obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BC is a member of the editorial board for the BMC Infectious Diseases journal. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"582"}}